- Home
- STAA vs VRDN Comparison
STAA vs VRDN Comparison
Compare STAA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAA
- VRDN
- Stock Information
- Founded
- STAA 1982
- VRDN 2006
- Country
- STAA United States
- VRDN United States
- Employees
- STAA N/A
- VRDN N/A
- Industry
- STAA Ophthalmic Goods
- VRDN Medical Specialities
- Sector
- STAA Health Care
- VRDN Health Care
- Exchange
- STAA Nasdaq
- VRDN Nasdaq
- Market Cap
- STAA 1.3B
- VRDN 1.5B
- IPO Year
- STAA N/A
- VRDN N/A
- Fundamental
- Price
- STAA $24.82
- VRDN $19.16
- Analyst Decision
- STAA Buy
- VRDN Buy
- Analyst Count
- STAA 7
- VRDN 12
- Target Price
- STAA $42.83
- VRDN $36.44
- AVG Volume (30 Days)
- STAA 615.8K
- VRDN 1.7M
- Earning Date
- STAA 10-30-2024
- VRDN 11-12-2024
- Dividend Yield
- STAA N/A
- VRDN N/A
- EPS Growth
- STAA 9.97
- VRDN N/A
- EPS
- STAA 0.44
- VRDN N/A
- Revenue
- STAA $341,224,000.00
- VRDN $302,000.00
- Revenue This Year
- STAA $8.37
- VRDN $2.55
- Revenue Next Year
- STAA $11.70
- VRDN N/A
- P/E Ratio
- STAA $56.42
- VRDN N/A
- Revenue Growth
- STAA 10.01
- VRDN N/A
- 52 Week Low
- STAA $23.72
- VRDN $11.40
- 52 Week High
- STAA $52.68
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- STAA 41.27
- VRDN 40.49
- Support Level
- STAA $23.90
- VRDN $17.06
- Resistance Level
- STAA $25.77
- VRDN $23.65
- Average True Range (ATR)
- STAA 1.45
- VRDN 1.25
- MACD
- STAA 0.01
- VRDN -0.02
- Stochastic Oscillator
- STAA 27.23
- VRDN 20.64
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.